Wednesday, 19 Feb 2020

You are here

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ).  A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

This UK study examined ONJ amongst those hospital admission with osteonecrosis of the jaw from 521,695 Million Women Study participants.

After a mean follow-up of 8.2 years, 100 women were hospitalized with their first ONJ. One-third (29/100) of the cases had used bisphosphonates.  The absolute risk ONJ hospitalizations for those at age 70 years was 0.09 per 1000 in non-bisphosphonate exposed and 0.69 per 1000 among those who use bisphosphonates (adjusted RR = 6.09, 95% CI 3.83–9.66; p < 0.0001). Bisphosphonates had an excess ONJ risk of 0.6/1000 users over a 5 year period. 

The risk for ONJ was also increased in women with a prior cancer (RR = 3.40, 2.22–5.22, p < 0.0001). 

In this UK population of postmenopausal women, use of oral bisphosphonates was associated with a 6-fold increased risk of hospital admission with osteonecrosis of the jaw.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hormone Therapy for Postmenopausal Women

The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?

Knee Replacements Last 25 Years

UK registry reports that greater than 80% of total knee replacements can last for 25 years.

The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial. 

ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis

Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. The ACR periodically updates guidelines to reflect any advances in management added to the literature since the last publication, which in this case was 2012.